FindMyKOL

Vivien Hsu, MD

Basic profile

Rutgers

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionNew Brunswick, NJ · NortheastSpecialtyRheumatologyFocusRheumatology/Immunology
Active KOLFindMyKOL type: NationalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Vivien Hsu is a Rheumatology/Immunology physician affiliated with Rutgers. OpenAlex indexes 96 publications with 15,190 citations (h-index 39). By OpenAlex citation count, this profile ranks in the top 10% of Rheumatology profiles in the FindMyKOL directory.

Overview

Scholarship

indexed output and impact (OpenAlex)
96publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

15,190citations

Citations across these publications.

39h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
4companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • GSK
    Program year202510 paymentsResearch
    $22,863
  • Boehringer Ingelheim Pharmaceuticals, Inc.
    Program year20255 payments
    $7,196
  • Novartis
    Program year20251 paymentResearch
    $733
All 12 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    29.3%
    Folate Analog Metabolic Inhibitor16.9%
    Methotrexate95%Methotrexate Sodium5%
    Part D<11 patients
    Kinase inhibitor7.6%
    Ofev100%
    Part D≥15 patients

    + 3 more classes in this area

  • Metabolism & gastrointestinal

    23.8%
    Proton pump inhibitor13.9%
    Omeprazole70%Pantoprazole Sodium30%
    Part D≥34 patients
    Corticosteroid7.8%
    Prednisone100%
    Part D≥42 patients

    + 1 more class in this area

  • Cardiovascular

    19%
    Endothelin Receptor Antagonist9.1%
    Ambrisentan78%Letairis13%Opsumit9%
    Part D<11 patients
    Calcium channel blocker5.8%
    Amlodipine Besylate63%Nifedipine Er37%
    Part D<11 patients

    + 3 more classes in this area

Where care is delivered (Part B)5.6% facility · 94.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”